Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
No upcoming events at this time.
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results